Navigation Links
Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment
Date:11/18/2009

New Patent Application covers technology to re-direct auto-immune related inflammation

San Diego (PRWEB) November 18, 2009 -- Entest BioMedical Inc. (OTCBB: ENTB) announced today the filing of a third patent application relating to the area of chronic obstructive pulmonary disease (COPD), a condition that affects more than 5 million patients in the United States, resulting in more than 120,000 deaths per year. The application covers an implantable medical device useful in re-directing the immune system to stop tissue inflammation.

“The importance of the inflammatory process in COPD is exemplified by the use of broad-acting steroids that reduce inflammation. Unfortunately, these drugs do not address the cause of the inflammation, and have a variety of adverse effects” Stated Dr. Stephen Josephs, inventor of the technology.

A recent article “Immunologic aspects of chronic obstructive pulmonary disease” by Cosio et al in the June 4th, 2009 issue of New England Medical Journal suggests that COPD may actually be not just a disease of inflammation but, of active immunological attack. The current technology seeks to induce a process in which immunity towards components of the body is blocked.

“To date Entest has filed two previous patent applications covering use of fat stem cell components in COPD and methods of using photoceuticals to enhance stem cell therapy. The current patent application has a variety of derivative uses outside of COPD including treatment of transplantation rejection, and other disease in which the immune system has gone awry” Stated David Koos, Entest’s CEO.

The essence of the technology is the use of existing implantable devices to deliver chemical/protein signals that specifically stop inflammatory reactions in a manner that is more in tune with biological processes. Instead of us “telling the body” what it should do with a blunt-force approach, as is the standard of care, the current invention uses more natural and slow acting interventions.

About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Contact:

David R. Koos, Chairman & CEO
619.702.1404 Direct
619.330.2328 Fax

Entest BioMedical Inc.
www.EntestBio.com

###

Read the full story at http://www.prweb.com/releases/chronic_obstructive/pulmonary_disease/prweb3225544.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Bio-Matrix Scientific Group and Entest BioMedical Sign Contract With UCLA Researcher to Develop Gestational Diabetes Screening Test
2. Entest BioMedical Inc. Adds Former National Cancer Institute Researcher to Scientific Advisory Board With Focus on Stem Cell Cancer Patient Therapies
3. Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company
4. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
5. Hopes, Predictions and Realities: Is Biomedical Research Delivering On Its Promises?
6. Dr. Andrew K. Palmer Joins BMEs (BioMedical Enterprises, Inc.) Board of Directors
7. BME (BioMedical Enterprises, Inc.) Announces U.S. Launch of the OSSArc(TM) Anatomic Residual Compression Implant
8. Response Biomedical Corporation Receives Conditional Listing Approval from the Toronto Stock Exchange
9. XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM)
10. American Red Cross Announces New Leader for Biomedical Services
11. New nanotube findings by Stanford researchers give boost to potential biomedical applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... CA (PRWEB) , ... February 11, 2016 , ... ... extensive experience performing a wide range of cosmetic procedures. Along with performing procedures, ... the efficiency and results of many cosmetic procedures. One of the most common ...
(Date:2/11/2016)... ... February 11, 2016 , ... The Chartis Group, a ... five firms in the “2015/2016 Best in KLAS: Software and Services” report in ... a research and insights firm on a global mission to improve healthcare delivery ...
(Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, Inc. (AIS) ... A Case Study for Plans and Purchasers.” Executives from Intel Corp. and Providence ... on value-based health benefits program Connected Care, will discuss the challenges they faced ...
(Date:2/11/2016)... ... February 11, 2016 , ... Life is known for throwing ... 60 and older, who gather once a year to play softball to raise money ... the game, the more than 50 players who competed in this year’s softball tournament ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... communities with their ongoing community involvement program, introduces a new charity campaign to ... children, donations are now being accepted at https://donate.rmhc.org/ . , Ronald McDonald ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Transformational M&A achieved through NPS and Dyax acquisitions ... Transformational M&A achieved through NPS and Dyax acquisitions and the ... M&A achieved through NPS and Dyax acquisitions and the announced ... with most robust pipeline in Shire , s ... most robust pipeline in Shire , s history ...
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 ... breast cancer market will experience considerable expansion from $1.9 billion ... Annual Growth Rate (CAGR) of 8.5%. --> Breast ... that the Asia-Pacific (APAC) breast cancer ... to $3.4 billion by 2021, at a Compound Annual Growth ...
(Date:2/11/2016)... ALBANY, New York , February 11, 2016 ... Research announces the release of a new research report, titled ... Growth, Trends and Forecast, 2013 - 2019". According to the ... expand at a 4.40% CAGR from 2013 to 2019, growing ... bn by 2019. --> --> ...
Breaking Medicine Technology: